A 76-year-old man diagnosed with severe pure native aortic regurgitation underwent transcatheter aortic valve replacement due to high surgical risk. The computed tomography angiography showed no calcification and no stenosis of the aortic...
A 76-year-old man diagnosed with severe pure native aortic regurgitation underwent transcatheter aortic valve replacement due to high surgical risk. The computed tomography angiography showed no calcification and no stenosis of the aortic...
A 56-year-old man presented with typical angina for 1 day and a prior history of exertional dyspnea of 6 months duration. Clinically, he was diagnosed with severe aortic regurgitation (AR). Electrocardiogram showed left ventricular...
A 56-year-old man presented with typical angina for 1 day and a prior history of exertional dyspnea of 6 months duration. Clinically, he was diagnosed with severe aortic regurgitation (AR). Electrocardiogram showed left ventricular...
Luca Oechslin, MD1; Patric Biaggi, MD1; Peter Wenaweser, MD1,2; Christophe Wyss, MD1; Daniel Fritschi, MD1; Oliver Gaemperli, MD1; Roberto Corti, MD1
Luca Oechslin, MD1; Patric Biaggi, M...
The authors report their experience of transcatheter aortic valve implantation with a balloon-expandable transcatheter heart valve in 8 consecutive patients with native aortic regurgitation at high surgical risk.
The authors report their experience of transcatheter aortic valve implantation with a balloon-expandable transcatheter heart valve in 8 consecutive patients with native aortic regurgitation at high surgical risk.
Neil Ruparelia, MD; Katharine Thomas, MD; James D. Newton, MD; Kate Grebenik, MD; Amar Keiralla, MD; George Krasopoulos, MD; Rana Sayeed, MD; Adrian P. Banning, MD; Rajesh K. Kharbanda, MD
Neil Ruparelia, MD; Katharine Thomas...
The first reported case series of the Lotus valve (Boston Scientific) for the treatment of surgical aortic bioprosthesis failure.
The first reported case series of the Lotus valve (Boston Scientific) for the treatment of surgical aortic bioprosthesis failure.
Christian Frerker, MD1; Jury Schewel, MD1; Dimitry Schewel, MD1; Peter Wohlmuth2; Tobias Schmidt, MD1; Felix Kreidel, MD1; Ralf Bader, MD3; Karl-Heinz Kuck, MD1; Ulrich Schäfer, MD1
Christian Frerker, MD1; Jury Schewel...
This study compares both the feasibility and outcomes of “off-label” transcatheter aortic valve replacement (TAVR) patients (n=156) with a standard “on-label” TAVR population (n=435) at a single institution.
This study compares both the feasibility and outcomes of “off-label” transcatheter aortic valve replacement (TAVR) patients (n=156) with a standard “on-label” TAVR population (n=435) at a single institution.
Paolo Scacciatella, MD1; Sebastiano Marra, MD1; Alberto Pullara, MD1,2; Federico Conrotto, MD1;
Matteo Marchetti, MD1,2; Gaetana Ferraro, MD1; Marco Pavani, MD1,2; Luigi Biasco, MD1,2;
Dario Bongiovanni, MD1; Fiorenzo Gaita, Prof, MD1,2; Fulvio Orzan, MD1,2
Paolo Scacciatella, MD1; Sebastiano ...
An investigation of the very long-term clinical outcomes of atrial septal defect (ASD) percutaneous closure in adult patients and evaluation of the 12-month effects of the device on aortic and mitral valve function. Transcatheter ASD closure...
An investigation of the very long-term clinical outcomes of atrial septal defect (ASD) percutaneous closure in adult patients and evaluation of the 12-month effects of the device on aortic and mitral valve function. Transcatheter ASD closure...